Ultragenyx Pharmaceutical Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RARE | QURE | DSGN | BBIO | PHAR | IVA | |
|---|---|---|---|---|---|---|
| Market cap | 1.69B | 1.60B | 665.24M | 15.17B | 881.90M | 914.17M |
| P/E (TTM) | — | — | — | — | 38.9 | — |
| Forward P/E | 76.1 | -7.8 | -6.6 | -225.0 | 69.2 | -5.2 |
| Price/book | -5.8 | 7.2 | 3.0 | -5.9 | 2.9 | 13.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −44.56% | −8.40% | +54.73% | +24.17% | −15.24% | −7.42% |
| Today | +3.19% | −3.52% | +2.80% | +5.21% | −3.63% | −3.97% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RARE news ›Ultragenyx granted conditional U.K. nod for Dojolvi
Ultragenyx Pharmaceutical’s (RARE) wins conditional marketing authorization in the U.K. for its rare disease therapy triheptanoin (Dojolvi). Read more here. - The U.K. drug regulator on Friday issued conditional marketing authorization for…
Ultragenyx Pharmaceutical (RARE) Set to Post Quarterly Earnings on Tuesday
Posted by Danessa Lincoln on Oct 27th, 2026 Shares of RARE opened at $16.08 on Tuesday. The company has a 50 day moving average price of $17.74 and a 200-day moving average price of $23.03. Ultragenyx Pharmaceutical has a fifty-two week…
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Average Target Price of $33.65
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has been assigned an average rating of “Hold” from the twenty-two brokerages that are currently covering the stock, MarketBeat.com reports.
Ultragenyx agrees to sell review voucher for $210M
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for…
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
Asia Broadband Board Approves Additional $18 Million for Stock Repurchases, Bringing Authorized Total Repurchases Up to $30 Million Click Holdings Limited (NASDAQ: CLIK) Reports Record Full-Year Results: Revenue, Gross Profit and Net…
More from 3 other outlets
- PharmExec Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
- @clin_trials Ultragenyx to Sell Rare Pediatric Disease Voucher for $210 Million
- Ultragenyx Pharmaceutical Inc. Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
Ultragenyx Pharmaceutical Inc. $RARE Stock Acquired by Assenagon Asset Management S.A.
MarketBeat Ultragenyx Pharmaceutical Inc. $RARE Stock Acquired by Assenagon Asset Management S.A. Assenagon Asset Management S.A. boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report)
Madison Avenue International LP Reports 6.4% Stake in Ultragenyx Pharmaceutical Inc.
Pegasystems (NASDAQ:PEGA) Missed, Yet Rallied: What’s Going On? Is Goldman Sachs (NYSE:GS) Benefiting From Capital Markets Activity? On October 20, 2026, a Schedule 13G filing revealed that Madison Avenue International LP along with…
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 7,066 Shares of Company Stock
Posted by Defense World Staff on Oct 20th, 2026 Shares of Ultragenyx Pharmaceutical stock opened at $15.07 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $12.73 and a 12 month high of $39.89. The business’s 50-day moving…
Ultragenyx passive stake reported at approximately 6.4%
Six parties report the same passive stake above 5% in Ultragenyx (RARE). Stock Titan - [SCHEDULE 13G] Ultragenyx Pharmaceutical Inc. Passive Investment Disclosure (>5%) Ultragenyx passive stake reported at approximately 6.4% The reported…
Ultragenyx sells second rare pediatric PRV in a week for $203m
The sale brings the company's combined voucher proceeds to $413 million, following the approval of two gene therapies within the same number of months. Ultragenyx has entered into a definitive agreement to sell a rare pediatric disease…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com12
- stocktitan.net6
- marketbeat.com3
- tradingview.com3
- bioxconomy.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 43 articles, not a forecast.